T2DM Patients Shown to Reduce A1C and Require Less Insulin Using Valeritas’ V-Go®
Retrospective analysis based on electronic records presented in a poster today at the OAAPN meeting in Columbus, Ohio
BRIDGEWATER, New Jersey, October 22, 2015 – Valeritas Inc. announced today the results of a retrospective chart review of 10 patients with T2DM on insulin therapy who switched to the V-Go® Disposable Insulin Delivery Device. The data were disclosed today in a poster presentation at the Ohio Association of Advanced Practices Nurses (OAAPN) meeting in Columbus, Ohio. The poster titled All Patients to Goal Using a Disposable Insulin Delivery Device in a Specialty Endocrine Practice: Comparison of A1Cs >9% or < 9%, was co-authored by Rebecca Lynn Ray, MSN, APRN, FNP-C at Endocrine Specialists in Toledo, Ohio and Susan Barlow, BS, BA, RDN, CDE, Associate Director, Medical Affairs, Field Medical Affairs at Valeritas.
The ten patients were selected from the electronic medical records of various endocrinologists. All had exceeded glycemic targets (A1C > 7.0) on multiple daily insulin injections (MDI) and had changed to the V-Go® disposable insulin delivery device. All were using V-Go® for a minimum of two follow-up visits. A1C, weight, and patient-reported hypoglycemia and hyperglycemia were collected at baseline and at each follow-up visit. Prescribed basal, bolus and Total Daily Dose (TDD) of insulin were also recorded at baseline and at each follow-up visit with A1C results.
Data showed that despite a baseline of A1C <9 or A1C >9, all patients were able to achieve a mean A1C <7 after 6 months using 27% less insulin after switching to V-Go®. All patients were also able to normalize insulin dosing, using <0.5 units/kg of body weight, regardless of body weight or baseline A1C.
“These results further support previous real world clinical data demonstrating that V-Go® helps patients to improve A1C levels and with less insulin. Patients with A1C >9 are at highest risk for diabetes-related complications. Decreasing A1C by using V-Go® may assist practices in achieving quality measures that will help patients experience less complications, which could translate into economic benefits including lower costs,” said Valeritas CEO, Kristine Peterson.
To receive a copy of this poster, please contact, [email protected].
About the V-Go® Disposable Insulin Delivery Device
V-Go® is a small, discreet, wearable and easy-to-use disposable insulin delivery solution for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. V-Go® enables patients to closely mimic the body's normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24–hour period and also providing for on-demand bolus dosing at mealtimes. V-Go® is mechanical and operates for 24 hours without electronics, batteries, infusion sets or programming. It is worn on the skin under clothing and measures just 2.4 inches wide by 1.3 inches long by 0.5 inches thick, weighing approximately one ounce when filled with insulin.
Important Risk Information: If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go® Disposable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go®: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go® use include skin irritation from the adhesive pad or infections at the infusion site. V-Go® should be removed before any magnetic resonance imaging (MRI) testing.
About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' flagship product, the V-Go®, is the first, simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a physiological, continuous, preset basal (continuous) rate infusion of insulin over 24 hours. It also provides on demand bolus dosing at mealtimes. It is the only basal bolus insulin delivery system on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D; functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Press Contact:
Marjie Hadad
MH Communications
[email protected]
908-947-0378